Anavex Life Sciences Corp
AVXL3.750USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
325.01MMarket Cap
LossP/E TTM
More Details of Anavex Life Sciences Corp Company
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Anavex Life Sciences Corp Info
Ticker SymbolAVXL
Company nameAnavex Life Sciences Corp
IPO dateApr 13, 2006
CEOMissling (Christopher U)
Number of employees34
Security typeOrdinary Share
Fiscal year-endApr 13
Address630 5Th Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10111
Phone18446893939
Websitehttps://www.anavex.com
Ticker SymbolAVXL
IPO dateApr 13, 2006
CEOMissling (Christopher U)
Company Executives of Anavex Life Sciences Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.09%
The Vanguard Group, Inc.
5.69%
State Street Investment Management (US)
3.68%
Geode Capital Management, L.L.C.
2.27%
Two Sigma Investments, LP
2.01%
Other
79.27%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.09%
The Vanguard Group, Inc.
5.69%
State Street Investment Management (US)
3.68%
Geode Capital Management, L.L.C.
2.27%
Two Sigma Investments, LP
2.01%
Other
79.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.48%
Investment Advisor/Hedge Fund
9.73%
Individual Investor
3.23%
Hedge Fund
2.64%
Bank and Trust
1.00%
Research Firm
0.93%
Pension Fund
0.24%
Venture Capital
0.09%
Insurance Company
0.03%
Other
59.63%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
361
33.18M
40.32%
+16.73K
2025Q3
374
33.16M
42.26%
+53.90K
2025Q2
368
33.05M
40.68%
+750.54K
2025Q1
357
32.28M
37.21%
+528.38K
2024Q4
346
29.86M
35.43%
+2.39M
2024Q3
332
27.21M
35.57%
+180.66K
2024Q2
332
27.06M
40.00%
-5.09M
2024Q1
328
32.30M
34.03%
+4.36M
2023Q4
332
26.28M
33.24%
+710.68K
2023Q3
327
25.50M
34.10%
-220.78K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
6.22M
7.24%
+237.96K
+3.98%
Jun 30, 2025
The Vanguard Group, Inc.
5.09M
5.92%
+204.62K
+4.19%
Jun 30, 2025
State Street Investment Management (US)
2.95M
3.43%
-265.45K
-8.26%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.02M
2.35%
+54.98K
+2.80%
Jun 30, 2025
Two Sigma Investments, LP
1.80M
2.09%
+428.37K
+31.31%
Jun 30, 2025
Missling (Christopher U)
1.51M
1.76%
+42.45K
+2.89%
Sep 11, 2025
Skarpelos (Athanasios)
1.31M
1.52%
--
--
Apr 25, 2025
Northwest Asset Management
1.02M
1.19%
+24.13K
+2.41%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
709.62K
0.83%
+39.70K
+5.93%
Jun 30, 2025
Northern Trust Investments, Inc.
715.06K
0.83%
+40.31K
+5.97%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.53%
ALPS Medical Breakthroughs ETF
0.27%
State Street SPDR S&P Biotech ETF
0.21%
iShares Micro-Cap ETF
0.13%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Vanguard US Momentum Factor ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Biotechnology ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.53%
ALPS Medical Breakthroughs ETF
Proportion0.27%
State Street SPDR S&P Biotech ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.13%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.13%
Vanguard US Momentum Factor ETF
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
iShares Biotechnology ETF
Proportion0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Anavex Life Sciences Corp?
The top five shareholders of Anavex Life Sciences Corp are:
BlackRock Institutional Trust Company, N.A. holds 6.22M shares, accounting for 7.24% of the total shares.
The Vanguard Group, Inc. holds 5.09M shares, accounting for 5.92% of the total shares.
State Street Investment Management (US) holds 2.95M shares, accounting for 3.43% of the total shares.
Geode Capital Management, L.L.C. holds 2.02M shares, accounting for 2.35% of the total shares.
Two Sigma Investments, LP holds 1.80M shares, accounting for 2.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.22M shares, accounting for 7.24% of the total shares.
The Vanguard Group, Inc. holds 5.09M shares, accounting for 5.92% of the total shares.
State Street Investment Management (US) holds 2.95M shares, accounting for 3.43% of the total shares.
Geode Capital Management, L.L.C. holds 2.02M shares, accounting for 2.35% of the total shares.
Two Sigma Investments, LP holds 1.80M shares, accounting for 2.09% of the total shares.
What are the top three shareholder types of Anavex Life Sciences Corp?
The top three shareholder types of Anavex Life Sciences Corp are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
How many institutions hold shares of Anavex Life Sciences Corp (AVXL)?
As of 2025Q4, 361 institutions hold shares of Anavex Life Sciences Corp, with a combined market value of approximately 33.18M, accounting for 40.32% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.94%.
What is the biggest source of revenue for Anavex Life Sciences Corp?
In --, the -- business generated the highest revenue for Anavex Life Sciences Corp, amounting to -- and accounting for --% of total revenue.
